{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:29:19Z","timestamp":1789500559685,"version":"build-2803163510"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Children with heterozygous familial hypercholesterolaemia (HeFH) show greater carotid intima-media thickness (cIMT). Evolocumab, a proprotein convertase subtilisin\/kexin type 9 inhibitor monoclonal antibody, substantially reduced LDL cholesterol (LDL-C) in children with HeFH. We investigated evolocumab\u2019s effect on cIMT progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>HAUSER-RCT was a randomized, placebo-controlled trial. One hundred fifty-seven paediatric patients with FH (age: 10\u201317 years) and LDL-C &amp;gt; 130\u2005mg\/dL despite statin therapy received monthly evolocumab 420\u2005mg or placebo for 24 weeks. Patients who continued into an open-label extension (OLE) (HAUSER-OLE; n = 150) received 80 weeks of monthly evolocumab plus statins. Carotid intima-media thickness was measured by B-mode ultrasound scanning of right and left common carotid artery at baseline; Week 24 of randomized controlled trial (RCT) (Day 1 OLE); and Weeks 24, 48, and 80 of OLE. Descriptive analysis of cIMT was a pre-specified HAUSER secondary endpoint, and inferential tests reported here were post hoc. One hundred fifty-one patients had evaluable cIMT summary scores at \u2265 1 visit. From RCT baseline to Week 24, mean cIMT increased by 0.006\u2005mm (SD = 0.05) with placebo (n = 37) and decreased by 0.003\u2005mm (SD = 0.05) with evolocumab (n = 76). From RCT baseline to OLE Week 80, mean cIMT summary score decreased by 0.019\u2005mm (SD = 0.04) and 0.012\u2005mm (SD = 0.05), respectively, in patients who initially received placebo (n = 34, P = 0.007) vs. receiving evolocumab throughout (n = 59, P = 0.067). Across patients who received evolocumab in OLE, mean cIMT significantly decreased by 0.011\u2005mm (SD = 0.05) from OLE Day 1 to Week 80 (n = 94, P = 0.034).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In children with HeFH, evolocumab plus statin treatment up to 104 weeks led to regression in carotid arterial wall thickening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov: NCT02624869<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwae369","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T15:20:49Z","timestamp":1731079249000},"page":"1548-1556","source":"Crossref","is-referenced-by-count":9,"title":["Evolocumab treatment reduces carotid intima-media thickness in paediatric patients with heterozygous familial hypercholesterolaemia"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6223-5671","authenticated-orcid":false,"given":"Albert","family":"Wiegman","sequence":"first","affiliation":[{"name":"Department of Paediatrics, Amsterdam UMC, Location AMC , Meibergdreef 9, 1105 AZ Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ruzza","sequence":"additional","affiliation":[{"name":"Clinical Development, Amgen Inc. , Thousand Oaks, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G Kees","family":"Hovingh","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam UMC, Location AMC , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul D","family":"Santos","sequence":"additional","affiliation":[{"name":"Lipid Clinic at the Heart Institute (InCor), University of S\u00e3o Paulo Medical School Hospital, Hospital Israelita Albert Einstein , S\u00e3o Paulo ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Mach","sequence":"additional","affiliation":[{"name":"Cardiology Department, Geneva University Hospitals , Geneva ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Stefanutti","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Umberto I Hospital, Sapienza University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse K","family":"Luirink","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Amsterdam UMC, Location AMC , Meibergdreef 9, 1105 AZ Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Bridges","sequence":"additional","affiliation":[{"name":"Biostatistics, Amgen Ltd , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Development, Amgen Inc. , Thousand Oaks, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Clinical Development, Amgen Inc. , Thousand Oaks, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick J","family":"Raal","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Faculty of Health Sciences, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J P","family":"Kastelein","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam UMC, Location AMC , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5185-3666","authenticated-orcid":false,"given":"Daniel","family":"Gaudet","sequence":"additional","affiliation":[{"name":"Clinical Lipidology and Rare Lipid Disorders Unit, Community Genomic Medicine Centre, ECOGENE-21, Department of Medicine, Universit\u00e9 de Montr\u00e9al , Chicoutimi, Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"key":"2026071319573606900_zwae369-B1","doi-asserted-by":"crossref","first-page":"17093","DOI":"10.1038\/nrdp.2017.93","article-title":"Familial hypercholesterolaemia","volume":"3","author":"Defesche","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2026071319573606900_zwae369-B2","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","article-title":"Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis","volume":"141","author":"Hu","year":"2020","journal-title":"Circulation"},{"key":"2026071319573606900_zwae369-B3","doi-asserted-by":"crossref","first-page":"III33","DOI":"10.1161\/01.CIR.0000131516.65699.ba","article-title":"Measurement of arterial wall thickness as a surrogate marker for atherosclerosis","volume":"109","author":"de Groot","year":"2004","journal-title":"Circulation"},{"key":"2026071319573606900_zwae369-B4","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jacl.2022.01.009","article-title":"Intima-media thickness in treated and untreated patients with and without familial hypercholesterolemia: a systematic review and meta-analysis","volume":"16","author":"van Bergen En Henegouwen","year":"2022","journal-title":"J Clin Lipidol"},{"key":"2026071319573606900_zwae369-B5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(04)15467-6","article-title":"Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia","volume":"363","author":"Wiegman","year":"2004","journal-title":"Lancet"},{"key":"2026071319573606900_zwae369-B6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1161\/CIRCRESAHA.114.301430","article-title":"Carotid intima-media thickness in children with familial hypercholesterolemia","volume":"114","author":"Kusters","year":"2014","journal-title":"Circ Res"},{"key":"2026071319573606900_zwae369-B7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.echo.2007.11.011","article-title":"Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine","volume":"21","author":"Stein","year":"2008","journal-title":"J Am Soc Echocardiogr"},{"key":"2026071319573606900_zwae369-B8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2022.11.011","article-title":"Cumulative dyslipidemia with arterial stiffness and carotid IMT progression in asymptomatic adolescents: a simulated intervention longitudinal study using temporal inverse allocation model","volume":"364","author":"Agbaje","year":"2023","journal-title":"Atherosclerosis"},{"key":"2026071319573606900_zwae369-B9","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-year follow-up of statins in children with familial hypercholesterolemia","volume":"381","author":"Luirink","year":"2019","journal-title":"N Engl J Med"},{"key":"2026071319573606900_zwae369-B10","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41569-021-00647-9","article-title":"Prevention of atherosclerosis from childhood","volume":"19","author":"Raitakari","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"2026071319573606900_zwae369-B11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1161\/CIRCULATIONAHA.116.025158","article-title":"Effect of rosuvastatin on carotid intima-media thickness in children with heterozygous familial hypercholesterolemia: the CHARON study (hypercholesterolemia in children and adolescents taking rosuvastatin open label)","volume":"136","author":"Braamskamp","year":"2017","journal-title":"Circulation"},{"key":"2026071319573606900_zwae369-B12","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/MOL.0000000000000177","article-title":"Early initiation of statin treatment in children with familial hypercholesterolaemia","volume":"26","author":"Braamskamp","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"2026071319573606900_zwae369-B13","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.292.3.331","article-title":"Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial","volume":"292","author":"Wiegman","year":"2004","journal-title":"JAMA"},{"key":"2026071319573606900_zwae369-B14","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.atherosclerosis.2019.11.012","article-title":"Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries","volume":"292","author":"Ramaswami","year":"2020","journal-title":"Atherosclerosis"},{"key":"2026071319573606900_zwae369-B15","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1542\/peds.2009-2107C","article-title":"Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report","volume":"128","author":"Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart Lung and Blood Institute","year":"2011","journal-title":"Pediatrics"},{"key":"2026071319573606900_zwae369-B16","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa2019910","article-title":"Evolocumab in pediatric heterozygous familial hypercholesterolemia","volume":"383","author":"Santos","year":"2020","journal-title":"N Engl J Med"},{"key":"2026071319573606900_zwae369-B17","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S2213-8587(22)00221-2","article-title":"Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT","volume":"10","author":"Santos","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026071319573606900_zwae369-B18","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jacl.2018.05.007","article-title":"Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: rationale and design of the HAUSER-RCT study","volume":"12","author":"Gaudet","year":"2018","journal-title":"J Clin Lipidol"},{"key":"2026071319573606900_zwae369-B19","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jacc.2020.07.059","article-title":"Time course of LDL cholesterol exposure and cardiovascular disease event risk","volume":"76","author":"Domanski","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026071319573606900_zwae369-B20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.atherosclerosis.2020.06.011","article-title":"SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia","volume":"306","author":"Gallo","year":"2020","journal-title":"Atherosclerosis"},{"key":"2026071319573606900_zwae369-B21","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0003319720975635","article-title":"The effect of long-term atorvastatin therapy on carotid intima-media thickness of children with dyslipidemia","volume":"72","author":"Karapostolakis","year":"2021","journal-title":"Angiology"},{"key":"2026071319573606900_zwae369-B22","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.297.12.1344","article-title":"Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial","volume":"297","author":"Crouse","year":"2007","journal-title":"JAMA"},{"key":"2026071319573606900_zwae369-B23","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1161\/HYPERTENSIONAHA.109.192639","article-title":"Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association","volume":"54","author":"Urbina","year":"2009","journal-title":"Hypertension"},{"key":"2026071319573606900_zwae369-B24","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"2026071319573606900_zwae369-B25","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026071319573606900_zwae369-B26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.atherosclerosis.2021.04.014","article-title":"Marked plaque regression in homozygous familial hypercholesterolemia","volume":"327","author":"Reeskamp","year":"2021","journal-title":"Atherosclerosis"},{"key":"2026071319573606900_zwae369-B27","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0002-9149(97)89309-5","article-title":"Relation of cholesterol-year score to severity of calcific atherosclerosis and tissue deposition in homozygous familial hypercholesterolemia","volume":"77","author":"Schmidt","year":"1996","journal-title":"Am J Cardiol"},{"key":"2026071319573606900_zwae369-B28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.atherosclerosis.2023.01.011","article-title":"When economy meets physiopathology: a novel cost-effectiveness model finally considers the cumulative effect of LDL cholesterol burden","volume":"367","author":"Carvalho","year":"2023","journal-title":"Atherosclerosis"},{"key":"2026071319573606900_zwae369-B29","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S2213-8587(23)00156-0","article-title":"Lipoprotein(a) and carotid intima-media thickness in children with familial hypercholesterolaemia in the Netherlands: a 20-year follow-up study","volume":"11","author":"de Boer","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026071319573606900_zwae369-B30","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/eurjpc\/zwae304","article-title":"Extension of heterozygous familial hypercholesterolemia treatment recommendations by including both low-density lipoprotein and lipoprotein(a) burden: a unique opportunity to improve patient prognosis","volume":"32","author":"Vuorio","year":"2026","journal-title":"Eur J Prev Cardiol"},{"key":"2026071319573606900_zwae369-B31","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1194\/jlr.P065334","article-title":"PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role","volume":"57","author":"Raal","year":"2016","journal-title":"J Lipid Res"},{"key":"2026071319573606900_zwae369-B32","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2459\/JCM.0000000000000611","article-title":"Adherence to proprotein convertase subtilisin\/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience","volume":"19","author":"Gragnano","year":"2018","journal-title":"J Cardiovasc Med (Hagerstown)"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwae369\/60896310\/zwae369.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/9\/1548\/60896310\/zwae369.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/9\/1548\/60896310\/zwae369.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:57:52Z","timestamp":1783987072000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/33\/9\/1548\/7896199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,12]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,11,12]]},"published-print":{"date-parts":[[2026,7,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwae369","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2024,11,12]]}}}